Answers are grounded in this paper and cite their sources.
Novel anti-leishmanial target LmSir2 has few subtle but prudent structural differences in ligand binding and catalytic domain as compared to its human counterpart. In silico screening and validation followed by in vitro deacetylation and cell killing assays described herein give a proof of concept for development of strategies exploiting such minor differences for screening libraries of small molecules to identify selective inhibitors.
No takes yet. Share an insight, caveat, or question.
Kadam et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: